Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pyxis Oncology, Inc. (PYXS)
USD2.40
+0.11 (+4.59%)
US NASDAQ Healthcare Biotechnology
Address
35 Cambridgepark Drive 2140
Boston, MA, US
Boston, MA, US
CEO
Thomas Civik
Website
pyxisoncology.com
IPO
2021-10-08
CIK 1782223 ISIN US7473241013
Description
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Apexigen, Inc. | APGN | 2023-06-08 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.40
+0.11 (+4.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
643.7K
Beta
1.43
Float Shares
40.40M
Free Float %
64.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.65% | -2.64% | +30.00% | +70.00% | -49.31% | +92.17% | +106.54% | -40.75% | -83.26% | -83.26% | -83.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
2.40
Low
5.00
+108.8%
Consensus
6.33
+164.3%
Median
6.00
+150.5%
High
8.00
+234.0%
DCF (Unlevered)
1.74
-27.2%
DCF (Levered)
0.38
-83.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
6.00
+150.5%
|
| Last Quarter | 1 |
6.00
+150.5%
|
| Last Year | 5 |
6.20
+158.9%
|
| All Time | 8 |
7.25
+202.7%
|
Quality scores
Altman Z-Score
-6.41
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-14.2%
-
EPS growth Biotechnology: +29.7%+3.0% Q1'26: -5.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-572.7%
-
EBIT margin Biotechnology: +0.0%-609.2%
-
ROIC Biotechnology: -16.1%-1,616.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.3% Q1'26: +4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.23× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 7 EPS Ana. |
Dec 2027 9 Rev. Ana. 7 EPS Ana. |
Dec 2028 9 Rev. Ana. 7 EPS Ana. |
Dec 2029 4 Rev. Ana. 2 EPS Ana. |
Dec 2030 4 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 16.15M (-100.0%)
|
16.15M
est: 16.11M (+0.2%)
|
13.86M
est: 2.84M (+388.4%)
|
43.8K
43.8K – 43.8K
-98.5% YoY
|
4.17M
4.17M – 4.17M
+9,423.8% YoY
|
13.81M
13.81M – 13.81M
+231.5% YoY
|
46.43M
46.43M – 46.43M
+236.2% YoY
|
115.20M
115.20M – 115.20M
+148.1% YoY
|
| EBITDA |
-80.27M
est: 3.23M (-2,585.7%)
|
-65.51M
est: 3.22M (-2,133.6%)
|
-79.91M
est: 567.4K (-14,182.7%)
|
8.7K
8.7K – 8.7K
-98.5% YoY
|
833.3K
833.3K – 833.3K
+9,424.9% YoY
|
2.76M
2.76M – 2.76M
+231.5% YoY
|
9.29M
9.29M – 9.29M
+236.2% YoY
|
23.04M
23.04M – 23.04M
+148.1% YoY
|
| EBIT |
-82.20M
est: 3.23M (-2,645.4%)
|
-68.50M
est: 3.22M (-2,226.2%)
|
-84.42M
est: 567.4K (-14,977.7%)
|
8.7K
8.7K – 8.7K
-98.5% YoY
|
833.3K
833.3K – 833.3K
+9,424.9% YoY
|
2.76M
2.76M – 2.76M
+231.5% YoY
|
9.29M
9.29M – 9.29M
+236.2% YoY
|
23.04M
23.04M – 23.04M
+148.1% YoY
|
| Net Income |
-73.79M
est: -81.84M (+9.8%)
|
-77.33M
est: -67.52M (-14.5%)
|
-79.62M
est: -79.62M (+0.0%)
|
-77.02M
-92.30M – -61.75M
+3.3% YoY
|
-83.38M
-107.94M – -58.81M
-8.2% YoY
|
-115.89M
-121.84M – -24.37M
-39.0% YoY
|
-62.38M
-62.38M – -62.38M
+46.2% YoY
|
-39.23M
-39.23M – -39.23M
+37.1% YoY
|
| SGA |
32.61M
est: 19.94M (+63.5%)
|
25.42M
est: 19.90M (+27.8%)
|
22.19M
est: 3.50M (+533.3%)
|
54.0K
54.0K – 54.0K
-98.5% YoY
|
5.15M
5.15M – 5.15M
+9,423.9% YoY
|
17.06M
17.06M – 17.06M
+231.5% YoY
|
57.35M
57.35M – 57.35M
+236.2% YoY
|
142.29M
142.29M – 142.29M
+148.1% YoY
|
| EPS |
-1.85
est: -1.32 (-40.5%)
|
-1.32
est: -1.09 (-20.9%)
|
-1.28
est: -1.33 (+4.1%)
|
-1.28
-1.49 – -0.99
+4.4% YoY
|
-1.31
-1.74 – -0.95
-3.0% YoY
|
-1.28
-1.96 – -0.39
+2.7% YoY
|
-1.00
-1.00 – -1.00
+21.5% YoY
|
-0.63
-0.63 – -0.63
+37.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-97.37M
OE per share TTM
-1.58
Owner's Yield
-69.41%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
315.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
18
Total invested
928.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ridgeback Capital Investments L.P. 66-0677421 | 4.35M | 9.80% | — | 4.35M | — | 4.35M | OO | Delaware | 2024-01-26 | ↗ |
| 2 | Ridgeback Capital Investments LLC 72-1614961 | 4.35M | 9.80% | — | 4.35M | — | 4.35M | OO | Delaware | 2024-01-26 | ↗ |
| 3 | Ridgeback Capital Management LLC 42-1684320 | 4.35M | 9.80% | — | 4.35M | — | 4.35M | OO | Delaware | 2024-01-26 | ↗ |
| 4 | David Kroin | 4.18M | 7.87% | — | 4.18M | — | — | HC, IN | Delaware | 2024-03-08 | ↗ |
| 5 | Deep Track Biotechnology Master Fund, Ltd. | 4.18M | 7.87% | — | 4.18M | — | — | CO | Delaware | 2024-03-08 | ↗ |
| 6 | Deep Track Capital, LP | 4.18M | 7.87% | — | 4.18M | — | — | IA, OO | Delaware | 2024-03-08 | ↗ |
| 7 | Benjamin Alexander Smith | 3.17M | 9.00% | — | 3.17M | — | — | IN | Delaware | 2023-02-08 | ↗ |
| 8 | Janaka Sheehan Maduraperuma | 3.17M | 9.00% | — | 3.17M | — | — | IN | Delaware | 2023-02-08 | ↗ |
| 9 | Laurion Capital Management LP | 3.17M | 9.00% | — | 3.17M | — | — | IA, PN | Delaware | 2023-02-08 | ↗ |
| 10 | Pfizer Inc. 13-5315170 | 2.99M | 9.13% | — | 2.99M | — | — | CO | — | 2022-02-11 | ↗ |
| 11 | Pfizer Ventures (US) LLC 82-5524518 | 2.99M | 9.13% | — | 2.99M | — | — | OO | — | 2022-02-11 | ↗ |
| 12 | RA Capital Management, L.P. | 2.28M | 7.00% | — | 2.28M | — | 2.28M | IA, PN | Delaware | 2022-02-14 | ↗ |
| 13 | RTW Investments, LP | 2.12M | 6.50% | — | 2.12M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 14 | Roderick Wong | 2.12M | 6.50% | — | 2.12M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 15 | Peter Kolchinsky | 1.91M | 5.80% | — | 1.91M | — | — | HC, IN | Delaware | 2021-10-25 | ↗ |
| 16 | Rajeev Shah | 1.91M | 5.80% | — | 1.91M | — | — | HC, IN | Delaware | 2021-10-25 | ↗ |
| 17 | BVF Inc. | 1.79M | 5.50% | — | — | — | 1.79M | CO | Delaware | 2021-12-20 | ↗ |
| 18 | BVF Partners L.P. | 1.79M | 5.50% | — | — | — | 1.79M | IA, PN | Delaware | 2021-12-20 | ↗ |
| 19 | Mark N. Lampert | 1.79M | 5.50% | — | — | — | 1.79M | IN | Delaware | 2021-12-20 | ↗ |
| 20 | RA Capital Healthcare Fund, L.P. | 1.69M | 5.10% | — | 1.69M | — | — | PN | Delaware | 2021-10-25 | ↗ |
| 21 | BVF GP HOLDINGS LLC | 1.67M | 5.10% | — | — | — | 1.67M | OO | Delaware | 2021-12-20 | ↗ |
| 22 | BVF I GP LLC | 942.1K | 2.90% | — | — | — | 942.1K | OO | Delaware | 2021-12-20 | ↗ |
| 23 | Biotechnology Value Fund, L.P. | 942.1K | 2.90% | — | — | — | 942.1K | PN | Delaware | 2021-12-20 | ↗ |
| 24 | BVF II GP LLC | 723.5K | 2.20% | — | — | — | 723.5K | OO | Delaware | 2021-12-20 | ↗ |
| 25 | Biotechnology Value Fund II, L.P. | 723.5K | 2.20% | — | — | — | 723.5K | PN | Delaware | 2021-12-20 | ↗ |
| 26 | BVF Partners OS Ltd. | 106.5K | 1.00% | — | — | — | 106.5K | CO | Delaware | 2021-12-20 | ↗ |
| 27 | Biotechnology Value Trading Fund OS LP | 106.5K | 1.00% | — | — | — | 106.5K | PN | Delaware | 2021-12-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
18
-63 vs prev Q
New positions
2
Closed positions
62
Increased
5
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PFIZER INC | 7.03M +— (+0.0%) | 8.09M -7.5M (-48.2%) | 11.24% -0.116 pp | 3.42% -0.149 pp | USD1.56 -26.3% | 5 qtrs — |
| 2 | LAURION CAPITAL MANAGEMENT LP | 4.80M +1.2M (+32.3%) | 5.52M -2.5M (-31.5%) | 7.67% +1.811 pp | 0.21% +0.067 pp | USD4.38 -73.7% | 17 qtrs — |
| 3 | VANGUARD GROUP INC | 2.34M +171.8K (+7.9%) | 2.69M -2.1M (-44.1%) | 3.73% +0.239 pp | 0.00% +0.000 pp | USD4.48 -74.3% | 17 qtrs — |
| 4 | PALO ALTO INVESTORS LP | 1.04M +— (+0.0%) | 1.19M -1.1M (-48.2%) | 1.66% -0.017 pp | 0.17% -0.260 pp | USD1.91 -39.8% | 6 qtrs — |
| 5 | 683 CAPITAL MANAGEMENT, LLC | 891.9K +366.9K (+69.9%) | 1.03M -139.8K (-12.0%) | 1.43% +0.578 pp | 0.04% -0.016 pp | USD2.24 -48.7% | 6 qtrs — |
| 6 | JANE STREET GROUP, LLC | 786.0K +482.3K (+158.8%) | 903.9K +229.7K (+34.1%) | 1.26% +0.766 pp | 0.00% +0.000 pp | USD1.13 +1.8% | 9 qtrs — |
| 7 | BLACKROCK, INC. | 784.1K +100.4K (+14.7%) | 901.7K -616.1K (-40.6%) | 1.25% +0.149 pp | 0.00% +0.000 pp | USD3.14 -63.4% | 6 qtrs — |
| 8 | MILLENNIUM MANAGEMENT LLC | 743.1K -72.2K (-8.9%) | 854.6K -955.5K (-52.8%) | 1.19% -0.129 pp | 0.00% 0.000 pp | USD2.43 -52.7% | 17 qtrs — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 728.4K +152.0K (+26.4%) | 837.6K -441.8K (-34.5%) | 1.16% +0.234 pp | 0.00% 0.000 pp | USD1.65 -30.3% | 15 qtrs — |
| 10 | HEALTHINVEST PARTNERS AB | 617.2K +617.2K (+100.0%) | 709.8K +709.8K (+100.0%) | 0.99% +0.987 pp | 0.23% +0.227 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 11 | BANK OF AMERICA CORP /DE/ | 587.9K -28.1K (-4.6%) | 676.0K -691.3K (-50.6%) | 0.94% -0.055 pp | 0.00% +0.000 pp | USD2.25 -48.9% | 17 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 577.2K +32.7K (+6.0%) | 664.2K -545.0K (-45.1%) | 0.92% +0.043 pp | 0.00% +0.000 pp | USD3.54 -67.5% | 17 qtrs — |
| 13 | LONGAEVA PARTNERS L.P. | 503.2K +— (+0.0%) | 578.7K -538.4K (-48.2%) | 0.80% -0.008 pp | 0.05% -0.113 pp | USD2.22 -48.2% | 2 qtrs — |
| 14 | UBS GROUP AG | 392.8K +19.0K (+5.1%) | 451.7K -378.0K (-45.6%) | 0.63% +0.024 pp | 0.00% 0.000 pp | USD1.70 -32.4% | 12 qtrs — |
| 15 | MARSHALL WACE, LLP | 389.8K +389.8K (+100.0%) | 448.2K +448.2K (+100.0%) | 0.62% +0.623 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 8 qtrs — |
| 16 | DECHENG CAPITAL LLC | 326.8K +— (+0.0%) | 375.8K -349.7K (-48.2%) | 0.52% -0.005 pp | 0.05% -0.076 pp | USD1.80 -36.1% | 9 qtrs — |
| 17 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 317.8K +317.8K (+100.0%) | 365.4K +365.4K (+100.0%) | 0.51% +0.508 pp | 0.00% +0.003 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 18 | XTX TOPCO LTD | 289.0K +271.3K (+1,533.0%) | 332.4K +293.1K (+745.9%) | 0.46% +0.433 pp | 0.01% +0.007 pp | USD1.15 +0.0% | 11 qtrs — |
| 19 | STATE STREET CORP | 241.6K +39.6K (+19.6%) | 277.9K -170.7K (-38.1%) | 0.39% +0.060 pp | 0.00% +0.000 pp | USD2.98 -61.4% | 17 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 188.1K +188.1K (+100.0%) | 216.4K +216.4K (+100.0%) | 0.30% +0.301 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 21 | GRAHAM CAPITAL MANAGEMENT, L.P. | 183.9K +183.9K (+100.0%) | 211.5K +211.5K (+100.0%) | 0.29% +0.294 pp | 0.01% +0.005 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 22 | BANK OF NEW YORK MELLON CORP | 165.0K +— (+0.0%) | 189.8K -176.6K (-48.2%) | 0.26% -0.003 pp | 0.00% +0.000 pp | USD3.97 -71.0% | 12 qtrs — |
| 23 | QUBE RESEARCH & TECHNOLOGIES LTD | 145.8K +115.0K (+373.3%) | 167.7K +99.3K (+145.2%) | 0.23% +0.183 pp | 0.00% +0.000 pp | USD1.32 -12.9% | 10 qtrs — |
| 24 | NEWEDGE WEALTH, LLC | 116.0K +— (+0.0%) | 133.4K -320.2K (-70.6%) | 0.19% -0.002 pp | 0.00% -0.005 pp | USD3.67 -68.7% | 6 qtrs — |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 108.4K -29.1K (-21.2%) | 124.7K -180.6K (-59.2%) | 0.17% -0.049 pp | 0.00% +0.000 pp | USD2.62 -56.1% | 11 qtrs — |
| 26 | TWO SIGMA INVESTMENTS, LP | 105.5K +59.0K (+126.9%) | 121.4K +18.1K (+17.6%) | 0.17% +0.094 pp | 0.00% +0.000 pp | USD1.62 -29.0% | 2 qtrs — |
| 27 | NORTHERN TRUST CORP | 101.9K +1.2K (+1.2%) | 117.2K -106.5K (-47.6%) | 0.16% +0.000 pp | 0.00% +0.000 pp | USD3.75 -69.3% | 17 qtrs — |
| 28 | QUADRATURE CAPITAL LTD | 100.5K +100.5K (+100.0%) | 115.6K +115.6K (+100.0%) | 0.16% +0.161 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 3 qtrs — |
| 29 | MORGAN STANLEY | 89.2K -17.4K (-16.3%) | 102.6K -134.1K (-56.6%) | 0.14% -0.030 pp | 0.00% +0.000 pp | USD2.07 -44.4% | 17 qtrs — |
| 30 | GOLDMAN SACHS GROUP INC | 86.1K -39.3K (-31.3%) | 99.1K -179.4K (-64.4%) | 0.14% -0.065 pp | 0.00% +0.000 pp | USD3.08 -62.7% | 8 qtrs — |
| 31 | CITADEL ADVISORS LLC | 75.5K +75.5K (+100.0%) | 86.8K +86.8K (+100.0%) | 0.12% +0.121 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 32 | TORONTO DOMINION BANK | 75.0K +75.0K (+100.0%) | 86.3K +86.3K (+100.0%) | 0.12% +0.120 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 33 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 72.7K -4.0K (-5.2%) | 83.6K -86.7K (-50.9%) | 0.12% -0.008 pp | 0.00% -0.002 pp | USD1.81 -36.5% | 15 qtrs — |
| 34 | OMERS ADMINISTRATION CORP | 67.0K +67.0K (+100.0%) | 77.1K +77.1K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 35 | CABLE CAR CAPITAL LLC | 61.6K +— (+0.0%) | 70.8K -65.9K (-48.2%) | 0.10% -0.001 pp | 0.00% -0.056 pp | USD1.80 -36.1% | 9 qtrs — |
| 36 | BARCLAYS PLC | 60.4K -3.7K (-5.8%) | 69.4K -165.8K (-70.5%) | 0.10% -0.007 pp | 0.00% +0.000 pp | USD2.30 -50.0% | 7 qtrs — |
| 37 | ROYAL BANK OF CANADA | 55.6K -22.4K (-28.8%) | 64.0K -109.0K (-63.0%) | 0.09% -0.037 pp | 0.00% +0.000 pp | USD1.96 -41.3% | 12 qtrs — |
| 38 | — | 53.0K +53.0K (+100.0%) | 61.0K +61.0K (+100.0%) | 0.08% +0.085 pp | 0.01% +0.014 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 39 | DIMENSIONAL FUND ADVISORS LP | 50.1K +13.6K (+37.1%) | 57.6K -23.5K (-29.0%) | 0.08% +0.021 pp | 0.00% +0.000 pp | USD1.78 -35.4% | 12 qtrs — |
| 40 | UNIVERSITY OF CHICAGO | 48.7K +— (+0.0%) | 56.0K -52.1K (-48.2%) | 0.08% -0.001 pp | 0.03% -0.026 pp | USD1.34 -14.2% | 13 qtrs — |
| 41 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 40.0K -15.0K (-27.3%) | 46.0K -76.1K (-62.3%) | 0.06% -0.025 pp | 0.03% -0.088 pp | USD1.41 -18.4% | 3 qtrs — |
| 42 | COMMONWEALTH EQUITY SERVICES, LLC | 39.8K -21.4K (-35.0%) | 45.7K -90.3K (-66.4%) | 0.06% -0.035 pp | 0.00% 0.000 pp | USD2.12 -45.8% | 8 qtrs — |
| 43 | HRT FINANCIAL LP | 39.6K +24.3K (+157.5%) | 45.0K +11.0K (+32.4%) | 0.06% +0.039 pp | 0.00% +0.000 pp | USD1.13 +1.8% | 3 qtrs — |
| 44 | LPL FINANCIAL LLC | 35.1K +21.1K (+150.7%) | 40.4K +9.3K (+29.9%) | 0.06% +0.034 pp | 0.00% +0.000 pp | USD1.86 -38.2% | 6 qtrs — |
| 45 | AMERICAN CENTURY COMPANIES INC | 31.9K +31.9K (+100.0%) | 36.7K +36.7K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 46 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 28.9K +28.9K (+100.0%) | 33.2K +33.2K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 47 | AVANZA FONDER AB | 27.3K +27.3K (+100.0%) | 31.4K +31.4K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 48 | CETERA INVESTMENT ADVISERS | 27.3K -500.0 (-1.8%) | 31.3K -30.3K (-49.1%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD3.00 -61.7% | 11 qtrs — |
| 49 | MAIA WEALTH LLC | 22.0K +22.0K (+100.0%) | 29.6K +29.6K (+100.0%) | 0.04% +0.035 pp | 0.01% +0.005 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 50 | BNP PARIBAS ARBITRAGE, SNC | 24.3K +22.6K (+1,314.0%) | 27.9K +24.1K (+632.5%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD1.18 -2.5% | 5 qtrs — |
| 51 | ENGINEERS GATE MANAGER LP | 22.8K +22.8K (+100.0%) | 26.2K +26.2K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 52 | TWO SIGMA ADVISERS, LP | 22.6K -29.9K (-56.9%) | 26.0K -90.6K (-77.7%) | 0.04% -0.049 pp | 0.00% 0.000 pp | USD2.22 -48.2% | 2 qtrs — |
| 53 | FOX RUN MANAGEMENT, L.L.C. | 22.6K +22.6K (+100.0%) | 26.0K +26.0K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.004 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 54 | ADVISOR GROUP HOLDINGS, INC. | 17.2K +2.0K (+13.2%) | 19.8K +324.0 (+1.7%) | 0.03% +0.003 pp | 0.00% +0.000 pp | USD2.03 -43.3% | 12 qtrs — |
| 55 | JEFFERIES FINANCIAL GROUP INC. | 16.0K +16.0K (+100.0%) | 18.4K +18.4K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 56 | FMR LLC | 12.9K -2.6K (-16.8%) | 14.8K -19.5K (-56.9%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD1.60 -28.1% | 11 qtrs — |
| 57 | PACES FERRY WEALTH ADVISORS, LLC | 11.4K +11.4K (+100.0%) | 13.2K +13.2K (+100.0%) | 0.02% +0.018 pp | 0.01% +0.005 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 58 | TOWER RESEARCH CAPITAL LLC (TRC) | 10.8K -2.2K (-16.7%) | 12.4K -16.4K (-56.9%) | 0.02% -0.004 pp | 0.00% -0.001 pp | USD1.90 -39.5% | 17 qtrs — |
| 59 | NEWEDGE ADVISORS, LLC | 10.3K +10.0K (+4,000.0%) | 11.8K +11.2K (+2,024.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD1.19 -3.4% | 12 qtrs — |
| 60 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.1K -725.0 (-6.7%) | 11.7K -12.5K (-51.7%) | 0.02% -0.001 pp | 0.00% -0.001 pp | USD1.54 -25.3% | 5 qtrs — |
| 61 | SIMPLEX TRADING, LLC | 9.8K +2.4K (+31.7%) | 11.3K -4.7K (-29.6%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD1.50 -23.3% | 7 qtrs — |
| 62 | BALYASNY ASSET MANAGEMENT L.P. | 8.2K +8.2K (+100.0%) | 9.5K +9.5K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 63 | WINTHROP CAPITAL MANAGEMENT, LLC | 6.0K +— (+0.0%) | 7.0K -6.0K (-46.2%) | 0.01% 0.000 pp | 0.00% -0.002 pp | USD1.56 -26.3% | 5 qtrs — |
| 64 | JPMORGAN CHASE & CO | 5.5K +1.0K (+22.2%) | 6.3K -3.7K (-36.7%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD2.26 -49.1% | 12 qtrs — |
| 65 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.0K +628.0 (+26.2%) | 3.5K -1.8K (-34.6%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.41 -18.4% | 5 qtrs — |
| 66 | CITIGROUP INC | 2.9K +1.6K (+126.5%) | 3.3K +494.0 (+17.4%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD2.25 -48.9% | 8 qtrs — |
| 67 | WELLS FARGO & COMPANY/MN | 2.3K +2.0K (+701.8%) | 2.6K +2.0K (+315.2%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.37 -16.1% | 13 qtrs — |
| 68 | FEDERATED HERMES, INC. | 1.9K +1.9K (+100.0%) | 2.2K +2.2K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 69 | GF FUND MANAGEMENT CO. LTD. | 1.3K -57.0 (-4.3%) | 1.5K -1.5K (-50.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.49 -22.8% | 5 qtrs — |
| 70 | NISA INVESTMENT ADVISORS, LLC | 961.00 +— (+0.0%) | 1.1K -1.0K (-48.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.06 +8.5% | 6 qtrs — |
| 71 | PHYSICIAN WEALTH ADVISORS, INC. | 943.00 +— (+0.0%) | 1.1K -1.0K (-48.2%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD1.10 +4.5% | 3 qtrs — |
| 72 | JONES FINANCIAL COMPANIES LLLP | 500.00 +— (+0.0%) | 575.00 -495.0 (-46.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.11 -45.5% | 7 qtrs — |
| 73 | US BANCORP \DE\ | 94.00 +94.0 (+100.0%) | 108.00 +108.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 74 | SRS CAPITAL ADVISORS, INC. | 14.00 +— (+0.0%) | 16.00 -15.0 (-48.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.21 -48.0% | 2 qtrs — |
| 75 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 12.00 +— (+0.0%) | 14.00 -13.0 (-48.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 -23.3% | 7 qtrs — |
| 76 | SBI SECURITIES CO., LTD. | 1.00 -1.0 (-50.0%) | 1.00 -3.0 (-75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +15.0% | 5 qtrs — |
| 77 | ACADIAN ASSET MANAGEMENT LLC | — -43.1K (-100.0%) | — -94.0K (-100.0%) | 0.00% -0.070 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 78 | PERSISTENT ASSET PARTNERS LTD | — -34.6K (-100.0%) | — -76.9K (-100.0%) | 0.00% -0.056 pp | 0.00% -0.053 pp | USD— | 2 qtrs SOLD |
| 79 | DRIEHAUS CAPITAL MANAGEMENT LLC | — -418.6K (-100.0%) | — -929.4K (-100.0%) | 0.00% -0.676 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 80 | PIER 88 INVESTMENT PARTNERS LLC | — -151.7K (-100.0%) | — -336.8K (-100.0%) | 0.00% -0.245 pp | 0.00% -0.063 pp | USD— | 8 qtrs SOLD |
| 81 | DIADEMA PARTNERS LP | — -150.0K (-100.0%) | — -333.0K (-100.0%) | 0.00% -0.242 pp | 0.00% -0.085 pp | USD— | 2 qtrs SOLD |
| 82 | PRUDENTIAL FINANCIAL INC | — -16.3K (-100.0%) | — -36.2K (-100.0%) | 0.00% -0.026 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 83 | CWM, LLC | — -414.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 84 | EVERSOURCE WEALTH ADVISORS, LLC | — -434.0 (-100.0%) | — -964.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 85 | SCHULHOFF & CO INC | — -275.0K (-100.0%) | — -610.5K (-100.0%) | 0.00% -0.444 pp | 0.00% -0.261 pp | USD— | 10 qtrs SOLD |
| 86 | STEMPOINT CAPITAL LP | — -689.5K (-100.0%) | — -1.5M (-100.0%) | 0.00% -1.114 pp | 0.00% -0.307 pp | USD— | 2 qtrs SOLD |
| 87 | TANG CAPITAL MANAGEMENT LLC | — -2.5M (-100.0%) | — -5.6M (-100.0%) | 0.00% -4.038 pp | 0.00% -0.214 pp | USD— | 4 qtrs SOLD |
| 88 | AQR CAPITAL MANAGEMENT LLC | — -13.8K (-100.0%) | — -30.7K (-100.0%) | 0.00% -0.022 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 89 | JACOBS LEVY EQUITY MANAGEMENT, INC | — -60.3K (-100.0%) | — -133.9K (-100.0%) | 0.00% -0.097 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 90 | WALLEYE CAPITAL LLC | — -119.6K (-100.0%) | — -265.4K (-100.0%) | 0.00% -0.193 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 91 | PERCEPTIVE ADVISORS LLC | — -1.2M (-100.0%) | — -2.6M (-100.0%) | 0.00% -1.903 pp | 0.00% -0.076 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 19 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 444.7K | 0.60% |
| 2 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 53.9K | 0.40% |
| 3 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 8.7K | 0.19% |
| 4 | iShares Biotechnology ETF IBB | 0.01% | 1.02M | 0.44% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.01% | 114.9K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 7.7K | 0.35% |
| 7 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 5.7K | 1.19% |
| 8 | Vanguard Extended Market ETF VXF | 0.00% | 983.1K | 0.05% |
| 9 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 27.7K | 0.43% |
| 10 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 14.9K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
10
Sells
0
Shares acquired
1.38M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,383,296
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | Wadhane Jitendra | Officer | A-Award | A | Stock Option (Right to Buy) | 262,635 | 1.36 | 357.2K | 262,635 | D | ↗ |
| 2026-03-24 | Palani Santhosh | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | Metzger Michael A | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | Lewis-Hall Freda C | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | HUMPHREY RACHEL | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | FLAVIN JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-03-24 | Cline Darren S | Director | A-Award | A | Stock Option (Right to Buy) | 45,867 | 1.36 | 62.4K | 45,867 | D | ↗ |
| 2026-02-03 | Civik Thomas | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 690,131 | 1.49 | 1.03M | 690,131 | D | ↗ |
| 2025-04-21 | HUMPHREY RACHEL | Director | S-Sale | D | Common Stock | 13,896 | 1.03 | 14.4K | 81,309 | D | ↗ |
| 2025-04-17 | HUMPHREY RACHEL | Director | S-Sale | D | Common Stock | 200 | 0.97 | 194.00 | 95,205 | D | ↗ |
| 2025-04-14 | HUMPHREY RACHEL | Director | S-Sale | D | Common Stock | 1,400 | 0.97 | 1.4K | 95,405 | D | ↗ |
| 2025-03-31 | Wadhane Jitendra | Officer | A-Award | A | Stock Option (Right to Buy) | 263,782 | 0.98 | 258.5K | 263,782 | D | ↗ |
| 2025-03-31 | Sullivan Lara | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 918,308 | 0.98 | 899.9K | 918,308 | D | ↗ |
| 2025-03-31 | Palani Santhosh | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | Metzger Michael A | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | Lewis-Hall Freda C | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | HUMPHREY RACHEL | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | FLAVIN JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | Connealy Pamela Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 414,163 | 0.98 | 405.9K | 414,163 | D | ↗ |
| 2025-03-31 | Cline Darren S | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2025-03-31 | Civik Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 36,979 | 0.98 | 36.2K | 36,979 | D | ↗ |
| 2024-12-23 | Wadhane Jitendra | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.67 | 250.5K | 150,000 | D | ↗ |
| 2024-12-23 | Sullivan Lara | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,135,000 | 1.67 | 1.90M | 1,135,000 | D | ↗ |
| 2024-12-23 | Connealy Pamela Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 310,000 | 1.67 | 517.7K | 310,000 | D | ↗ |
| 2024-11-26 | Connealy Pamela Ann | Officer | P-Purchase | A | Common Stock | 83,400 | 1.96 | 163.5K | 1,199,143 | I | ↗ |
| 2024-06-10 | Metzger Michael A | Director | A-Award | A | Stock Option (Right to Buy) | 70,683 | 3.97 | 280.6K | 70,683 | — | ↗ |
| 2024-06-07 | Palani Santhosh | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2024-03-26 | Wadhane Jitendra | Officer | A-Award | A | Common Stock | 131,484 | 0.00 | — | 398,421 | — | ↗ |
| 2024-03-26 | Sullivan Lara | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,071,242 | 3.83 | 4.10M | 1,071,242 | — | ↗ |
| 2024-03-26 | Lewis-Hall Freda C | Director | A-Award | A | Common Stock | 35,219 | 0.00 | — | 241,405 | — | ↗ |
| 2024-03-26 | HUMPHREY RACHEL | Director | A-Award | A | Common Stock | 38,741 | 0.00 | — | 96,805 | — | ↗ |
| 2024-03-26 | FLAVIN JOHN L | Director | A-Award | A | Common Stock | 35,219 | 0.00 | — | 413,015 | — | ↗ |
| 2024-03-26 | Dupont Jakob | Director | A-Award | A | Common Stock | 38,741 | 0.00 | — | 38,741 | — | ↗ |
| 2024-03-26 | Connealy Pamela Ann | Officer | A-Award | A | Common Stock | 328,710 | 0.00 | — | 1,110,293 | — | ↗ |
| 2024-03-26 | Cline Darren S | Director | A-Award | A | Common Stock | 35,219 | 0.00 | — | 251,405 | — | ↗ |
| 2024-03-26 | Civik Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 44,024 | 3.83 | 168.6K | 44,024 | — | ↗ |
| 2024-03-12 | Palani Santhosh | Director | A-Award | A | Stock Option (Right to Buy) | 69,760 | 5.70 | 397.6K | 69,760 | — | ↗ |
| 2023-12-29 | Kobayashi Ken | Officer | A-Award | A | Stock Option (Right to Buy) | 443,514 | 1.80 | 798.3K | 443,514 | — | ↗ |
| 2023-11-29 | Connealy Pamela Ann | Officer | F-InKind | D | Common Stock | 36,949 | 1.40 | 51.7K | 781,583 | — | ↗ |
| 2023-11-27 | Kobayashi Ken | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-15 | Wadhane Jitendra | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 266,937 | — | ↗ |
| 2023-09-28 | Connealy Pamela Ann | Officer | P-Purchase | A | Common Stock | 8,000 | 1.87 | 15.0K | 818,532 | — | ↗ |
| 2023-09-27 | Wadhane Jitendra | Officer | P-Purchase | A | Common Stock | 2,500 | 1.87 | 4.7K | 226,937 | — | ↗ |
| 2023-09-27 | Connealy Pamela Ann | Officer | P-Purchase | A | Common Stock | 6,426 | 1.85 | 11.9K | 810,532 | — | ↗ |
| 2023-09-25 | Wadhane Jitendra | Officer | P-Purchase | A | Common Stock | 5,000 | 1.77 | 8.9K | 224,437 | — | ↗ |
| 2023-09-25 | Connealy Pamela Ann | Officer | P-Purchase | A | Common Stock | 12,000 | 1.67 | 20.0K | 804,106 | — | ↗ |
| 2023-09-22 | Wadhane Jitendra | Officer | P-Purchase | A | Common Stock | 2,500 | 1.74 | 4.3K | 219,437 | — | ↗ |
| 2023-09-22 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to Buy) | 392,461 | 1.60 | 627.9K | 392,461 | — | ↗ |
| 2023-09-22 | Connealy Pamela Ann | Officer | P-Purchase | A | Common Stock | 5,000 | 1.74 | 8.7K | 792,106 | — | ↗ |
| 2023-09-18 | Sullivan Lara | Director / Officer | S-Sale | D | Common Stock | 8,541 | 2.10 | 17.9K | 2,403,882 | — | ↗ |
| 2023-09-14 | Sullivan Lara | Director / Officer | S-Sale | D | Common Stock | 100 | 2.25 | 225.00 | 2,412,423 | — | ↗ |
| 2023-09-13 | Sullivan Lara | Director / Officer | S-Sale | D | Common Stock | 3,000 | 2.27 | 6.8K | 2,597,265 | — | ↗ |
| 2023-09-12 | Sullivan Lara | Director / Officer | S-Sale | D | Common Stock | 4,917 | 2.25 | 11.1K | 2,600,265 | — | ↗ |
| 2023-09-11 | Sullivan Lara | Director / Officer | S-Sale | D | Common Stock | 20,000 | 2.27 | 45.4K | 2,605,182 | — | ↗ |
| 2023-09-07 | Wadhane Jitendra | Officer | A-Award | A | Common Stock | 93,896 | 0.00 | — | 211,937 | — | ↗ |
| 2023-09-07 | Sullivan Lara | Director / Officer | A-Award | A | Common Stock | 469,483 | 0.00 | — | 2,625,182 | — | ↗ |
| 2023-09-07 | Connealy Pamela Ann | Officer | A-Award | A | Common Stock | 187,793 | 0.00 | — | 782,106 | — | ↗ |
| 2023-08-23 | Dupont Jakob | Director | A-Award | A | Stock Option (Right to buy) | 17,250 | 15.37 | 265.1K | 17,250 | — | ↗ |
| 2023-03-24 | Yanchik Connealy Pamela | Officer | A-Award | A | Common Stock | 209,803 | 0.00 | — | 594,313 | — | ↗ |
| 2023-03-24 | Wadhane Jitendra | Officer | A-Award | A | Stock Option (Right to buy) | 157,257 | 2.21 | 347.5K | 157,257 | — | ↗ |
| 2023-03-24 | Sullivan Lara | Director / Officer | A-Award | A | Stock Option (Right to buy) | 990,461 | 2.21 | 2.19M | 990,461 | — | ↗ |
| 2023-03-24 | Lewis-Hall Freda C | Director | A-Award | A | Common Stock | 139,355 | 0.00 | — | 206,186 | — | ↗ |
| 2023-03-24 | HUMPHREY RACHEL | Director | A-Award | A | Common Stock | 58,064 | 0.00 | — | 58,064 | — | ↗ |
| 2023-03-24 | Feingold Jay | Officer | A-Award | A | Stock Option (Right to buy) | 17,517 | 2.21 | 38.7K | 17,517 | — | ↗ |
| 2023-03-24 | FLAVIN JOHN L | Director | A-Award | A | Common Stock | 139,355 | 0.00 | — | 377,796 | — | ↗ |
| 2023-03-24 | Cline Darren S | Director | A-Award | A | Common Stock | 139,355 | 0.00 | — | 216,186 | — | ↗ |
| 2023-03-24 | Civik Thomas | Director | A-Award | A | Common Stock | 139,355 | 0.00 | — | 206,186 | — | ↗ |
| 2023-03-17 | PFIZER INC | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value per share | 1,811,594 | 2.76 | 5.00M | 5,952,263 | — | ↗ |
| 2023-01-03 | Yanchik Connealy Pamela | Officer | A-Award | A | Common Stock | 43,493 | 0.00 | — | 384,510 | — | ↗ |
| 2023-01-03 | Sullivan Lara | Officer | A-Award | A | Common Stock | 95,684 | 0.00 | — | 1,452,320 | — | ↗ |
| 2023-01-03 | Feingold Jay | Officer | A-Award | A | Common Stock | 53,931 | 0.00 | — | 520,542 | — | ↗ |
| 2022-10-06 | Pfizer Ventures (US) LLC | Director | — | D | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 4,140,669 | — | ↗ |
| 2022-08-11 | HUMPHREY RACHEL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-03 | Wadhane Jitendra | Officer | — | D | Common Stock | 0 | 0.00 | — | 43,648 | — | ↗ |
| 2022-04-26 | BARCLAYS PLC | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-25 | BARCLAYS PLC | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 3,477,945 | — | ↗ |
| 2022-04-21 | Chin Mark | Director | S-Sale | D | Common Stock | 1,745,761 | 3.05 | 5.32M | 0 | — | ↗ |
| 2022-04-14 | Yanchik Connealy Pamela | Officer | A-Award | A | Common Stock | 93,493 | 0.00 | — | 341,017 | — | ↗ |
| 2022-04-14 | Sullivan Lara | Officer | A-Award | A | Common Stock | 315,273 | 0.00 | — | 1,356,636 | — | ↗ |
| 2022-04-14 | Feingold Jay | Officer | A-Award | A | Common Stock | 115,931 | 0.00 | — | 466,611 | — | ↗ |
| 2022-03-31 | Yanchik Connealy Pamela | Director / Officer | A-Award | A | Common Stock | 247,524 | 0.00 | — | 247,524 | — | ↗ |
| 2022-03-31 | Sullivan Lara | Director / Officer | A-Award | A | Common Stock | 742,574 | 0.00 | — | 1,041,363 | — | ↗ |
| 2022-03-31 | Lewis-Hall Freda C | Director | A-Award | A | Common Stock | 66,831 | 0.00 | — | 66,831 | — | ↗ |
| 2022-03-31 | Feingold Jay | Director / Officer | A-Award | A | Common Stock | 306,930 | 0.00 | — | 350,680 | — | ↗ |
| 2022-03-31 | FLAVIN JOHN L | Director | A-Award | A | Common Stock | 66,831 | 0.00 | — | 238,441 | — | ↗ |
| 2022-03-31 | Cline Darren S | Director | A-Award | A | Common Stock | 66,831 | 0.00 | — | 76,831 | — | ↗ |
| 2022-03-31 | Civik Thomas | Director | A-Award | A | Common Stock | 66,831 | 0.00 | — | 66,831 | — | ↗ |
| 2022-03-31 | Chin Mark | Director | A-Award | A | Common Stock | 66,831 | 0.00 | — | 66,831 | — | ↗ |
| 2021-12-08 | Cline Darren S | Director | P-Purchase | A | Common Stock | 10,000 | 9.39 | 93.9K | 10,000 | — | ↗ |
| 2021-12-06 | Yanchik Connealy Pamela | Officer | A-Award | A | Stock Option (Right to buy) | 52,944 | 9.64 | 510.4K | 52,944 | — | ↗ |
| 2021-11-18 | Civik Thomas | Director | P-Purchase | A | Common Stock | 15,700 | 12.74 | 200.0K | 15,700 | — | ↗ |
| 2021-10-13 | FLAVIN JOHN L | Director | C-Conversion | D | Series B Convertible Preferred Stock | 15,190 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Cormorant Asset Management, LP | — | C-Conversion | D | Series B Convertible Preferred Stock | 668,854 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Chin Mark | Director | C-Conversion | A | Common Stock | 1,433,261 | 0.00 | — | 1,433,261 | — | ↗ |
| 2021-10-13 | Bayer World Investments B.V. | — | C-Conversion | A | Common Stock | 2,742,338 | 0.00 | — | 2,742,338 | — | ↗ |
| 2021-10-07 | Yanchik Connealy Pamela | Director / Officer | — | D | Stock Option (Right to buy) | 10,304 | 8.71 | 89.7K | — | — | ↗ |
| 2021-10-07 | Sullivan Lara | Director / Officer | — | D | Stock Option (Right to buy) | 990,461 | 5.34 | 5.29M | 0 | — | ↗ |
| 2021-10-07 | Shah Ritu | Director / Officer | — | D | Stock Option (Right to buy) | 7,212 | 8.71 | 62.8K | — | — | ↗ |
| 2021-10-07 | Lewis-Hall Freda C | Director | — | D | Stock Option (Right to buy) | 15,725 | 8.71 | 137.0K | — | — | ↗ |
| 2021-10-07 | Herbst Ronald | Director / Officer | — | D | Stock Option (Right to buy) | 10,304 | 8.71 | 89.7K | — | — | ↗ |
| 2021-10-07 | Feingold Jay | Director / Officer | — | D | Stock Option (Right to buy) | 17,517 | 8.71 | 152.6K | — | — | ↗ |
| 2021-10-07 | FLAVIN JOHN L | Director | — | D | Stock Option (Right to buy) | 15,725 | 8.71 | 137.0K | — | — | ↗ |
| 2021-10-07 | Cormorant Private Healthcare Fund III LP | Director | — | I | Series B Convertible Preferred Stock | 668,854 | 0.00 | — | — | — | ↗ |
| 2021-10-07 | Cormorant Asset Management, LP | 10% Owner | — | I | Series B Convertible Preferred Stock | 668,854 | 0.00 | — | 0 | — | ↗ |
| 2021-10-07 | Cline Darren S | Director | — | D | Stock Option (Right to buy) | 15,725 | 8.71 | 137.0K | — | — | ↗ |
| 2021-10-07 | Civik Thomas | Director | — | D | Stock Option (Right to buy) | 15,725 | 8.71 | 137.0K | — | — | ↗ |
| 2021-10-07 | Chin Mark | Director | — | D | Stock Option (Right to buy) | 15,725 | 8.71 | 137.0K | — | — | ↗ |
| 2021-10-07 | BAYER AKTIENGESELLSCHAFT | Director | — | D | Series B Convertible Preferred Stock | 955,507 | 0.00 | — | — | — | ↗ |
Executive team
Top executives
EBIT / Employee
-19.2K
Shares Outstanding
62.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Lara Sullivan, M.D. Former President, Chief Executive Officer and Chief Medical Officer | 646.9K | — | — | 723.1K | 291.1K | 10.5K | 1.67M | 43.26% | ↗ |
| 2 | 2025 | Pamela Connealy Former Chief Financial Officer and Chief Operating Officer | 262.8K | — | 402.4K | 349.1K | — | 411.0K | 1.43M | 52.73% | ↗ |
| 3 | 2025 | Jitendra Wadhane Principal Financial and Accounting Officer | 414.0K | — | — | 207.7K | 134.6K | 10.5K | 766.8K | 27.09% | ↗ |
| 4 | 2024 | Lara Sullivan, M.D. President, Chief Executive Officer and Chief Medical Officer | 625.0K | — | 1.25M | 4.77M | 421.9K | 10.4K | 7.07M | 85.05% | ↗ |
| 5 | 2024 | Lara Sullivan, M.D. Former President, Chief Executive Officer and Chief Medical Officer | 625.0K | — | 1.25M | 4.77M | 421.9K | 10.4K | 7.07M | 85.05% | ↗ |
| 6 | 2024 | Pamela Connealy Chief Financial Officer and Chief Operating Officer | 504.0K | — | 1.41M | 393.6K | 249.5K | 10.4K | 2.57M | 70.29% | ↗ |
| 7 | 2024 | Pamela Connealy Former Chief Financial Officer and Chief Operating Officer | 504.0K | — | 1.41M | 393.6K | 249.5K | 10.4K | 2.57M | 70.29% | ↗ |
| 8 | 2024 | Ken Kobayashi, M.D. Former Chief Medical Officer | 500.0K | — | — | — | 140.0K | 10.4K | 650.4K | 0.00% | ↗ |
| 9 | 2023 | Lara Sullivan, M.D. President and Chief Executive Officer | 625.0K | 200.0K | 2.69M | 546.1K | 375.0K | 9.9K | 4.44M | 72.77% | ↗ |
| 10 | 2023 | Lara Sullivan, M.D. President, Chief Executive Officer and Chief Medical Officer | 625.0K | 200.0K | 2.69M | 546.1K | 375.0K | 9.9K | 4.44M | 72.77% | ↗ |
| 11 | 2023 | Pamela Connealy Chief Financial Officer and Chief Operating Officer | 473.0K | — | 923.7K | 188.0K | 226.8K | 9.9K | 1.82M | 61.03% | ↗ |
| 12 | 2023 | Jay Feingold, M.D., Ph.D. Former Chief Medical Officer | 229.2K | — | 538.1K | 97.1K | — | 286.2K | 1.05M | 60.29% | ↗ |
| 13 | 2023 | Ken Kobayashi, M.D. Chief Medical Officer | 49.2K | — | — | 812.1K | 18.6K | — | 880.0K | 92.29% | ↗ |
| 14 | 2023 | Ken Kobayashi, M.D. Former Chief Medical Officer | 49.2K | — | — | 812.1K | 18.6K | — | 880.0K | 92.29% | ↗ |
| 15 | 2022 | Lara Sullivan, M.D. President and Chief Executive Officer | 565.0K | — | 4.15M | — | 301.4K | 9.9K | 5.03M | 82.57% | ↗ |
| 16 | 2022 | Lara Sullivan, M.D., President and Chief Executive Officer | 565.0K | — | 4.15M | — | 301.4K | 9.6K | 5.03M | 82.57% | ↗ |
| 17 | 2022 | Jay Feingold, M.D., Ph.D. Former Chief Medical Officer | 500.0K | — | 1.66M | — | 220.4K | 9.9K | 2.39M | 69.49% | ↗ |
| 18 | 2022 | Jay Feingold, M.D., Ph.D., Chief Medical Officer | 500.0K | — | 1.66M | — | 220.4K | 9.6K | 2.39M | 69.50% | ↗ |
| 19 | 2022 | Pamela Connealy Chief Financial Officer and Chief Operating Officer | 430.0K | — | 1.34M | — | 245.5K | 9.9K | 2.03M | 66.18% | ↗ |
| 20 | 2022 | Pamela Connealy, Chief Financial Officer and Chief Operating Officer | 430.0K | — | 1.34M | — | 245.5K | 9.6K | 2.03M | 66.19% | ↗ |
| 21 | 2021 | Lara Sullivan, M.D., Chief Executive Officer | 565.0K | — | — | 16.36M | 341.8K | — | 17.27M | 94.75% | ↗ |
| 22 | 2021 | Lara Sullivan, M.D., President and Chief Executive Officer | 565.0K | — | — | 16.36M | 341.8K | — | 17.27M | 94.75% | ↗ |
| 23 | 2021 | Jay Feingold, M.D., Ph.D., Chief Medical Officer | 151.5K | — | 700.0K | 6.60M | 255.1K | — | 7.71M | 94.73% | ↗ |
| 24 | 2021 | Jay Feingold, M.D., Ph.D. Chief Medical Officer | 151.5K | — | 700.0K | 6.60M | 255.1K | — | 7.71M | 94.73% | ↗ |
| 25 | 2021 | Pamela Connealy Chief Financial Officer | 195.5K | — | — | 2.27M | 252.5K | 18.8K | 2.74M | 82.94% | ↗ |
| 26 | 2021 | Pamela Connealy, Chief Financial Officer and Chief Operating Officer | 195.5K | — | — | 2.27M | 252.5K | 18.8K | 2.74M | 82.94% | ↗ |
| 27 | 2020 | Lara Sullivan, M.D., Chief Executive Officer | 375.0K | — | — | — | 180.0K | — | 555.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Civik | Interim CEO & Director | 47.5K | male |
| Balu N. Balasubramanian | Interim Chief Technology Officer | — | — |
| Charles T. Gombar | Senior Vice President of Portfolio & Program Management | — | — |
| Chris Cohen | Head of Drug Safety & Pharmacovigilance | — | — |
| Donna Regalado | Head of Human Resources | — | — |
| Hongwei Wang | Head of ADC Development & Clinical Strategy | — | — |
| Jan Pinkas | Chief Scientific Officer | — | — |
| Alex Kane | Senior Vice President of Investor Relations & Capital Markets | — | male |
| Marsha Crochiere | Head of Translational Medicine & Research | — | female |
| Michael Bui | Head of Global Regulatory Affairs | — | — |
| Shui He | Head of Biometrics | — | — |
| Stephen T. Worsley | Senior Vice President & Chief Business Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PYXS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
